Results 171 to 180 of about 2,791,761 (381)

Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells

, 2008
Marios Giannakis, Swaine L. Chen, Sherif M. Karam, Lars Engstrand, Jeffrey I. Gordon   +4 more
openalex   +1 more source

Type 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 1, January 2026.
Individuals with type 1 diabetes exhibit significantly increased prevalence of additional autoimmune diseases. Epidemiological, familial and mechanistic evidence indicates frequent polyautoimmunity and shared genetic and environmental drivers. Coexistence complicates clinical management, and autoantibody‐based detection often identifies preclinical ...
George J. Kahaly, Thomas Forst, Monika Kellerer, Stefanie Lanzinger, René D. Rötzer, Matthias Schott, Petra‐Maria Schumm‐Draeger   +6 more
wiley   +1 more source

In-vivo evaluation of apocynin for prevention of Helicobacter pylori-induced gastric carcinogenesis [PDF]

, 2017
Akagi, Allen, Arora, Ayala, Barnes, Cadamuro, Castor, Chandan, Connell, Conway, de Almeida, Dunn, Elfvin, Eruslanov, Ghosh, Guang, Gustavson, Handa, Hardbower, Harsha, Hougee, Kennett, Lafeber, Lull, Malfertheiner, McManus, Mózsik, Müller, Pedroso, Philippens, Rodriguez, Rubin, Stefanska, Stefanska, Tang, Umamaheshwari, Wang, Wiedemann, Xu, Yamazaki, Zhang, Zhao   +41 more
core   +2 more sources

Traditional Chinese Medicine nursing for a patient with chronic gastritis and constipation

, 2023
Xuemin HOU, Yanping HUANG, Mingzhu LI
openalex   +1 more source

Mechanisms of Action Involved in the In Vivo Gastroprotective Response of Fruits: A Systematic Review

Food Frontiers, Volume 7, Issue 1, January 2026.
ABSTRACT Gastrointestinal diseases remain a significant global health concern, primarily due to the limitations of current pharmacological treatments, which often come with adverse side effects and high recurrence rates. This situation highlights the urgent need for safer and more effective alternatives.
Isabel Sousa Alcântara, Renata Torres Pessoa, Lucas Yure Santos da Silva, Tarcisio Mendes Silva, Isis Oliveira Menezes, Anita Oliveira Brito Pereira Bezerra Martins, Irwin Rose Alencar de Menezes, Almir Gonçalves Wanderley   +7 more
wiley   +1 more source

Safety and Tolerability of Withania somnifera Root Extract in Healthy Male Participants: A Pilot Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
Withania somnifera (WS) or Ashwagandha is valued for its anti‐inflammatory, antioxidant, adaptogenic, and memory‐enhancing properties. This randomized, placebo‐controlled and double‐blind study assessed the safety of standardized WS root extract in healthy adult participants over 180 days. The study concluded that WS root extract (200 mg capsules twice
Narendra Vaidya, Ramshyam Agarwal, Pankaj Kshirsagar, Gayatri Ganu, Dheeraj Nagore, Anirudh Mehta, Ashit Vora, Sujit Nair   +7 more
wiley   +1 more source

Expression of P53 and C-erbB-2 and their significances in chronic atrophic gastritis

, 2006
Song Zhao, Yingmei Fu, Bai Zhao, Lianxin Liu   +3 more
openalex   +1 more source

A Liquid Thickener Presentation Format for the Therapeutic Management of Dysphagia—A Promising Step Forward in Addressing the Challenges Associated With Thickened Fluids in Swallowing Disorders?

International Journal of Language &Communication Disorders, Volume 61, Issue 1, January/February 2026.
ABSTRACT Introduction Thickening fluids in routine care of patients with Oropharyngeal dysphagia (OD) can improve swallow safety but may be counteracted by reduced palatability, enjoyment, embarrassment, and isolation related to drinking thickened fluids (TFs).
Natascha Ullrich, Brenda Mossel, Sue Pownall, Jo Burke, Helena Perry, Heather Robinson, John Stephenson   +6 more
wiley   +1 more source

THE CASE OF MELLORI-WEISS SYNDROME FORMATION IN PATIENT WITH CHRONIC NON-ATROPHIC GASTRITIS DURING A TRIP TO THE SANATORIUM [PDF]

, 2020
А. А. Авраменко
openalex   +1 more source

Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 137-150, January 2026.
Abstract Aims There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D.
Alex E. Henney, David R. Riley, Megan Heague, Carl A. Roberts, Theresa J. Hydes, Matthew Anson, David M. Hughes, Uazman Alam, Daniel J. Cuthbertson   +8 more
wiley   +1 more source